Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Itolizumab> ?p ?o }
Showing triples 1 to 60 of
60
with 100 triples per page.
- Itolizumab abstract "Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation. A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo. Biocon received marketing authorization for the drug from the Drugs Controller General of India (DCGI) in January 2013 and marketing within India commenced in August 2013.".
- Itolizumab atcPrefix "none".
- Itolizumab casNumber "1116433-11-4".
- Itolizumab fdaUniiCode "XQQ2RHV14N".
- Itolizumab wikiPageID "33052137".
- Itolizumab wikiPageLength "3387".
- Itolizumab wikiPageOutDegree "12".
- Itolizumab wikiPageRevisionID "602018034".
- Itolizumab wikiPageWikiLink Biocon.
- Itolizumab wikiPageWikiLink CD6.
- Itolizumab wikiPageWikiLink Category:Monoclonal_antibodies.
- Itolizumab wikiPageWikiLink Co-stimulation.
- Itolizumab wikiPageWikiLink Cytokine.
- Itolizumab wikiPageWikiLink Drug_Controller_General_of_India.
- Itolizumab wikiPageWikiLink Drugs_Controller_General_of_India.
- Itolizumab wikiPageWikiLink International_Nonproprietary_Name.
- Itolizumab wikiPageWikiLink Monoclonal_antibody.
- Itolizumab wikiPageWikiLink Psoriasis.
- Itolizumab wikiPageWikiLink Psoriasis_Area_and_Severity_Index.
- Itolizumab wikiPageWikiLink T_cell.
- Itolizumab wikiPageWikiLinkText "Itolizumab".
- Itolizumab wikiPageWikiLinkText "itolizumab".
- Itolizumab atcPrefix "none".
- Itolizumab casNumber "1116433".
- Itolizumab chemspiderid "NA".
- Itolizumab hasPhotoCollection Itolizumab.
- Itolizumab legalStatus "Approved in India".
- Itolizumab mabType "mab".
- Itolizumab source "zu".
- Itolizumab target CD6.
- Itolizumab tradename "Alzumab".
- Itolizumab type "mab".
- Itolizumab unii "XQQ2RHV14N".
- Itolizumab verifiedfields "changed".
- Itolizumab verifiedrevid "458270653".
- Itolizumab wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Itolizumab wikiPageUsesTemplate Template:Drugbox.
- Itolizumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Itolizumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Itolizumab subject Category:Monoclonal_antibodies.
- Itolizumab hypernym u2018.
- Itolizumab type Article.
- Itolizumab type ChemicalSubstance.
- Itolizumab type Drug.
- Itolizumab type Person.
- Itolizumab type Antibody.
- Itolizumab type Article.
- Itolizumab type Chemical.
- Itolizumab type Drug.
- Itolizumab type ChemicalObject.
- Itolizumab type Thing.
- Itolizumab type Q8386.
- Itolizumab comment "Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.".
- Itolizumab label "Itolizumab".
- Itolizumab sameAs إيتوليزوماب.
- Itolizumab sameAs m.0h551rm.
- Itolizumab sameAs Q6094826.
- Itolizumab sameAs Q6094826.
- Itolizumab wasDerivedFrom Itolizumab?oldid=602018034.
- Itolizumab isPrimaryTopicOf Itolizumab.